Eli Lilly’s revenue rose 48%, powered by stronger-than-expected demand for Mounjaro and Zepbound, its diabetes and weight-loss GLP-1 treatments.
4:45 PMMarketWatch36 stories from 10 sources
GLP-1 momentum grows as public health faces fresh tests
Day’s Recap
Supporting Articles
Analysts raised their Eli Lilly price target after the company exceeded expectations and increased its outlook again. Strong demand for its GLP-1 medicines remains the main driver of the bullish view.
3:28 PMCNBC
CDC and FDA are investigating a Salmonella outbreak linked to jalapenos from Mexico that has sickened 345 people across 27 states. A recall is underway.
9:13 AMCNBC
The Senate confirmed Erica Schwartz to lead the CDC as the agency faces political pressure and ongoing public health crises. Her appointment comes during a period of broader turmoil for the US public health agency.
6:46 PMAl Jazeera
The FDA has approved Moderna's influenza vaccine, making it the first licensed flu shot based on messenger RNA technology.
10:18 PMStat News
Novo Nordisk created the leading GLP-1 weight-loss drug franchise, but Eli Lilly moved faster and captured control of the market. The reversal shows how quickly an apparent European pharmaceutical advantage can erode in a strategically important global industry.
12:52 PMMarketWatch
Novo Nordisk's CEO defended the commercial outlook for a daily Wegovy pill as falling prices and intensifying competition from Eli Lilly pressured sales and drove the company's shares lower. Investors remain unconvinced that the obesity-drug maker has a clear route back to durable growth.
7:02 AMCNBC
The Ebola outbreak is appearing increasingly deadly because many patients are reaching treatment only after the disease has become critical.
5:57 AMBloomberg Markets
The delayed disclosure of another child's death in a gene-editing trial in China has renewed criticism of the country's clinical-trial transparency and safety practices. Experts are questioning whether a looser trial environment is allowing serious risks to remain hidden or underexamined.
1:46 PMStat News
Federal health officials are holding closed-door meetings with technology companies, researchers, and lobbyists as they consider how to accelerate clinical AI adoption.
4:05 PMStat News4:45 PMMarketWatch
Lilly’s revenue soars 48%, driven by demand for its GLP-1s
Summary
Eli Lilly’s revenue rose 48%, powered by stronger-than-expected demand for Mounjaro and Zepbound, its diabetes and weight-loss GLP-1 treatments.
The growth confirms that Lilly’s commercial momentum is concentrated in a fast-expanding but competitive drug
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
GLP-1 demand is reshaping Lilly’s growth profile and accelerating the broader shift toward obesity medicines as a major pharmaceutical market.
2 stories · 2 sources
3:28 PMCNBC
We're increasing our Eli Lilly price target after another beat-and-raise quarter
Summary
Analysts raised their Eli Lilly price target after the company exceeded expectations and increased its outlook again. Strong demand for its GLP-1 medicines remains the main driver of the bullish view.
Another beat-and-raise quarter strengthens the case that Lilly’s growth is becoming structural rather than a
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Lilly’s performance shows how GLP-1 drugs are reshaping pharmaceutical earnings and investor expectations.
9:13 AMCNBC
Mexican jalapenos tied to Salmonella outbreak in 27 U.S. states
Summary
CDC and FDA are investigating a Salmonella outbreak linked to jalapenos from Mexico that has sickened 345 people across 27 states. A recall is underway.
The outbreak's multistate spread has triggered a coordinated federal investigation and product recall. Consumers, retailers,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The scale of the outbreak raises the risk of further illnesses before contaminated products are fully identified and removed.
6:46 PMAl Jazeera
Erica Schwartz confirmed as new CDC chief amid US agency turmoil
Summary
The Senate confirmed Erica Schwartz to lead the CDC as the agency faces political pressure and ongoing public health crises. Her appointment comes during a period of broader turmoil for the US public health agency.
Schwartz takes control of the CDC at a moment when political scrutiny could complicate its
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The CDC's leadership change could affect the credibility and effectiveness of US public health responses.
4 stories · 4 sources
10:18 PMStat News
FDA approves Moderna’s mRNA flu vaccine, the first to use the technology
Summary
The FDA has approved Moderna's influenza vaccine, making it the first licensed flu shot based on messenger RNA technology.
FDA approval moves mRNA flu vaccination from development into clinical use and gives Moderna a
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The approval expands the mRNA platform beyond COVID-19 and could reshape how future seasonal flu vaccines are developed.
12:52 PMMarketWatch
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
Summary
Novo Nordisk created the leading GLP-1 weight-loss drug franchise, but Eli Lilly moved faster and captured control of the market. The reversal shows how quickly an apparent European pharmaceutical advantage can erode in a strategically important global industry.
Eli Lilly's success shifted pricing power, investor attention, and market momentum away from Novo Nordisk.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The GLP-1 race is becoming a test of Europe's ability to turn scientific breakthroughs into durable industrial power.
7:02 AMCNBC
Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%
Summary
Novo Nordisk's CEO defended the commercial outlook for a daily Wegovy pill as falling prices and intensifying competition from Eli Lilly pressured sales and drove the company's shares lower. Investors remain unconvinced that the obesity-drug maker has a clear route back to durable growth.
Lower pricing is weakening the economics of Novo's core obesity franchise just as Lilly expands
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The obesity-drug race is shifting from a supply-constrained growth story to a pricing and profitability contest.
2 stories · 2 sources
5:57 AMBloomberg Markets
Ebola Outbreak: Why the Death Rate Is Rising as Patients Reach Care Too Late
Summary
The Ebola outbreak is appearing increasingly deadly because many patients are reaching treatment only after the disease has become critical.
Late presentation, rather than clear evidence of a more lethal virus, is driving the rise
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A higher death rate may reflect failures in access and timing that can still be addressed through faster diagnosis and treatment.
1:46 PMStat News
STAT+: Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety
Summary
The delayed disclosure of another child's death in a gene-editing trial in China has renewed criticism of the country's clinical-trial transparency and safety practices. Experts are questioning whether a looser trial environment is allowing serious risks to remain hidden or underexamined.
The second reported death increases pressure for timely disclosure, independent oversight, and clearer evidence that
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Pediatric gene-editing research cannot earn legitimacy if deaths emerge late and oversight remains difficult to assess.
4:05 PMStat News
STAT+: Federal regulators invite industry, researchers, and lobbyists to closed-door meetings on clinical AI
Summary
Federal health officials are holding closed-door meetings with technology companies, researchers, and lobbyists as they consider how to accelerate clinical AI adoption.
The meetings signal that regulators are moving from broad interest in clinical AI toward policies
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The resulting framework could determine how quickly AI enters patient care and who bears responsibility when it fails.
Other Developments
A curated list of other prominent stories from this day.
Tiny particles from smoke, soot, and dust may worsen rheumatoid arthritis and increase the risk of painful flares, especially after prolonged exposure. The findings suggest that air quality could influence disease activity.
11:32 PMScienceDaily
A prescription THC treatment eliminated recurring trauma-related nightmares for more than one-third of people with PTSD after ten weeks. The result points to a potential treatment for a symptom that often persists despite existing care.
11:16 PMScienceDailyDermatologists recommend a range of products for removing blackheads, from pore strips costing $8 to higher-tech devices. The selection focuses on tools intended to clear clogged pores during the summer.
5:24 PMWWDThe menopause treatment market has grown into a $19 billion industry, drawing companies into a rapidly expanding commercial opportunity. The boom has not reached all women equally.
5:07 PMBloomberg Markets
The FDA approved Takeda’s narcolepsy treatment, marking a regulatory win for a novel drug class. Researchers hope the same approach could eventually address other conditions.
4:41 PMStat News
A proposed change to Medicare’s hospice payment system could save the federal government $7.6 billion annually. Hospice providers argue that the current model gives them flexibility to tailor care to individual patients.
10:04 AMMarketWatchAstraZeneca has explored acquiring Bristol Myers Squibb, according to people familiar with the matter. The potential transaction would be the largest merger in the pharmaceutical industry.
2:22 PMBloomberg Markets
A small trial found that some participants became more tolerant of peanuts after receiving a fecal microbiome transplant in pill form. The findings suggest that gut bacteria may influence food allergy responses, but they remain preliminary.
2:10 PMStat News
Bank of America spends about $250 million annually on GLP-1 drugs for employees, reflecting the high cost of covering medicines such as Ozempic and Wegovy. Employers are facing sustained demand for these treatments despite their multithousand-dollar annual price tags.
12:18 PMCNBC
CVS exceeded quarterly expectations and raised its outlook as its insurance business continued to recover. It also partnered with Eli Lilly to offer eligible patients access to Zepbound and Foundayo through the CVS Health app.
10:15 AMCNBC
Featherweight boxer Raven Chapman is recovering after collapsing during sparring on July 24 and undergoing emergency surgery for a brain bleed, according to her team.
9:58 AMAl JazeeraModerna has launched an early-stage clinical trial of an mRNA vaccine targeting Ebola. The trial marks an initial test of whether the platform can be applied to a disease with substantial outbreak risk but limited commercial demand.
9:32 AMStat News
Schrödinger CEO Ramy Farid is rethinking the company's approach to artificial intelligence. The discussion also covers Recursion's neuron map and other developments in health AI.
9:29 AMStat News
An analysis found that New York City classrooms serving students with disabilities are less likely to receive lead-paint inspections, even though children in those settings may face greater exposure risks. A child was poisoned at The Bronx School for Continuous Learners.
6:00 AMGothamist
A case in China illustrates the risks surrounding gene therapy, a treatment with the potential to produce profound medical benefits but also serious ethical consequences.
12:00 AMFinancial Times11:32 PMScienceDaily
Dirty air may trigger painful rheumatoid arthritis flares
Summary
Tiny particles from smoke, soot, and dust may worsen rheumatoid arthritis and increase the risk of painful flares, especially after prolonged exposure. The findings suggest that air quality could influence disease activity.
Prolonged exposure to particulate pollution may add an environmental trigger to rheumatoid arthritis, a disease
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Air pollution could become a preventable factor in managing rheumatoid arthritis symptoms.
11:16 PMScienceDaily
THC medication made PTSD nightmares disappear for more than a third of patients
Summary
A prescription THC treatment eliminated recurring trauma-related nightmares for more than one-third of people with PTSD after ten weeks. The result points to a potential treatment for a symptom that often persists despite existing care.
The key shift is that a prescription THC formulation produced complete nightmare relief for a
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A targeted treatment for persistent PTSD nightmares could address a major gap in symptom control.
5:24 PMWWD
The 12 Best Blackhead Removal Tools for Clearing Your Skin This Summer, According to Dermatologists
Summary
Dermatologists recommend a range of products for removing blackheads, from pore strips costing $8 to higher-tech devices. The selection focuses on tools intended to clear clogged pores during the summer.
The market spans inexpensive disposable products and more costly gadgets, giving consumers several ways to
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Blackhead care illustrates how expert-backed consumer skincare continues to expand across price points.
5:07 PMBloomberg Markets
Big Take: The $19 Billion Menopause Economy
Summary
The menopause treatment market has grown into a $19 billion industry, drawing companies into a rapidly expanding commercial opportunity. The boom has not reached all women equally.
The market is expanding faster than access, leaving some women excluded from new treatments and
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Menopause is becoming a major healthcare market, but growth alone will not resolve gaps in access.
4:41 PMStat News
STAT+: Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
Summary
The FDA approved Takeda’s narcolepsy treatment, marking a regulatory win for a novel drug class. Researchers hope the same approach could eventually address other conditions.
The approval gives the emerging drug class its first major clinical validation and expands options
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A successful new treatment platform could reshape narcolepsy care and open a path to therapies for other neurological disorders.
10:04 AMMarketWatch
Changing how Medicare pays for hospice care could save the U.S. $7.6 billion a year — but at what cost to patients?
Summary
A proposed change to Medicare’s hospice payment system could save the federal government $7.6 billion annually. Hospice providers argue that the current model gives them flexibility to tailor care to individual patients.
The central tradeoff is lower federal spending versus less flexibility in end-of-life care. A payment
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Medicare policy could reduce costs while changing how much support dying patients and their families receive.
2:22 PMBloomberg Markets
AstraZeneca Is Said to Have Explored Bristol Myers Merger
Summary
AstraZeneca has explored acquiring Bristol Myers Squibb, according to people familiar with the matter. The potential transaction would be the largest merger in the pharmaceutical industry.
The talks, if pursued, would signal that scale and pipeline depth are driving another wave
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A deal of this size could reset pharmaceutical industry valuations and concentrate power over major drug pipelines.
2:10 PMStat News
STAT+: Could poop pills be the next treatment for food allergies?
Summary
A small trial found that some participants became more tolerant of peanuts after receiving a fecal microbiome transplant in pill form. The findings suggest that gut bacteria may influence food allergy responses, but they remain preliminary.
The early signal points to the microbiome as a possible target for treating food allergies
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
If validated, microbiome-based treatment could offer a new way to reduce the danger of severe food-allergic reactions.
12:18 PMCNBC
Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says
Summary
Bank of America spends about $250 million annually on GLP-1 drugs for employees, reflecting the high cost of covering medicines such as Ozempic and Wegovy. Employers are facing sustained demand for these treatments despite their multithousand-dollar annual price tags.
The spending shows that GLP-1 coverage has become a major employer health-benefit expense rather than
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
GLP-1 drugs are reshaping employer healthcare budgets and benefit design.
10:15 AMCNBC
CVS blows past estimates, hikes guidance as insurance unit continues to improve
Summary
CVS exceeded quarterly expectations and raised its outlook as its insurance business continued to recover. It also partnered with Eli Lilly to offer eligible patients access to Zepbound and Foundayo through the CVS Health app.
The insurance unit’s improvement is restoring confidence in CVS’s core earnings and giving management room
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
CVS is combining an improving insurance business with direct distribution of obesity drugs, strengthening its influence over how patients obtain them.
9:58 AMAl Jazeera
Boxer Chapman recovering after emergency surgery for brain bleed
Summary
Featherweight boxer Raven Chapman is recovering after collapsing during sparring on July 24 and undergoing emergency surgery for a brain bleed, according to her team.
The incident underscores the potentially catastrophic consequences of head trauma in combat sports, even during
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A serious training-room brain injury puts athlete safety protocols in combat sports under renewed focus.
9:32 AMStat News
STAT+: Moderna launches early trial of Ebola mRNA vaccine
Summary
Moderna has launched an early-stage clinical trial of an mRNA vaccine targeting Ebola. The trial marks an initial test of whether the platform can be applied to a disease with substantial outbreak risk but limited commercial demand.
An Ebola program tests mRNA technology beyond the large markets that drove its initial growth.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The trial could show whether mRNA vaccines can address diseases that offer little conventional commercial incentive.
9:29 AMStat News
STAT+: Why Schrödinger CEO Ramy Farid changed how he’s thinking about AI
Summary
Schrödinger CEO Ramy Farid is rethinking the company's approach to artificial intelligence. The discussion also covers Recursion's neuron map and other developments in health AI.
The shift suggests that AI strategy in drug discovery is moving from broad enthusiasm toward
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Drug developers are becoming more selective about which AI applications can produce real scientific and commercial gains.
6:00 AMGothamist
Child poisoned as NYC special education classrooms lag in lead-paint inspections
Summary
An analysis found that New York City classrooms serving students with disabilities are less likely to receive lead-paint inspections, even though children in those settings may face greater exposure risks. A child was poisoned at The Bronx School for Continuous Learners.
The decisive failure is uneven inspection coverage in classrooms where vulnerable children spend their days.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Weak inspection standards can turn an existing disability risk into a preventable public-health threat.
12:00 AMFinancial Times
The ethical perils of gene therapy
Summary
A case in China illustrates the risks surrounding gene therapy, a treatment with the potential to produce profound medical benefits but also serious ethical consequences.
The central shift is that gene therapy's risks extend beyond technical safety to questions of
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Gene therapy can permanently alter patients' lives, making weak oversight especially difficult to reverse.
Make it yours
Build Your First Pass.
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!